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miR-27a and miR-27b regulate autophagic
clearance of damaged mitochondria by
targeting PTEN-induced putative kinase 1
(PINK1)
Jaekwang Kim1*, Fabienne C. Fiesel1, Krystal C. Belmonte1, Roman Hudec1, Wang-Xia Wang2, Chaeyoung Kim1,
Peter T. Nelson2, Wolfdieter Springer1,3 and Jungsu Kim1,3*
Abstract
Background: Loss-of-function mutations in PINK1 and PARKIN are the most common causes of autosomal recessive
Parkinson’s disease (PD). PINK1 is a mitochondrial serine/threonine kinase that plays a critical role in mitophagy, a
selective autophagic clearance of damaged mitochondria. Accumulating evidence suggests mitochondrial dysfunction
is one of central mechanisms underlying PD pathogenesis. Therefore, identifying regulatory mechanisms of PINK1
expression may provide novel therapeutic opportunities for PD. Although post-translational stabilization of PINK1 upon
mitochondrial damage has been extensively studied, little is known about the regulation mechanism of PINK1 at the
transcriptional or translational levels.
Results: Here, we demonstrated that microRNA-27a (miR-27a) and miR-27b suppress PINK1 expression at the
translational level through directly binding to the 3′-untranslated region (3′UTR) of its mRNA. Importantly, our data
demonstrated that translation of PINK1 is critical for its accumulation upon mitochondrial damage. The accumulation
of PINK1 upon mitochondrial damage was strongly regulated by expression levels of miR-27a and miR-27b. miR-27a
and miR-27b prevent mitophagic influx by suppressing PINK1 expression, as evidenced by the decrease of ubiquitin
phosphorylation, Parkin translocation, and LC3-II accumulation in damaged mitochondria. Consequently, miR-27a and
miR-27b inhibit lysosomal degradation of the damaged mitochondria, as shown by the decrease of the delivery of
damaged mitochondria to lysosome and the degradation of cytochrome c oxidase 2 (COX2), a mitochondrial marker.
Furthermore, our data demonstrated that the expression of miR-27a and miR-27b is significantly induced under chronic
mitophagic flux, suggesting a negative feedback regulation between PINK1-mediated mitophagy and miR-27a and
miR-27b.
Conclusions: We demonstrated that miR-27a and miR-27b regulate PINK1 expression and autophagic clearance of
damaged mitochondria. Our data further support a novel negative regulatory mechanism of PINK1-mediated
mitophagy by miR-27a and miR-27b. Therefore, our results considerably advance our understanding of PINK1
expression and mitophagy regulation and suggest that miR-27a and miR-27b may represent potential therapeutic
targets for PD.
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Background
Parkinson’s disease (PD), the second most common neu-
rodegenerative disorder, is clinically manifested by motor
symptoms, such as bradykinesia, resting tremor, rigidity,
and postural instability [1]. PD is pathologically character-
ized by the loss of dopaminergic neurons in substantia
nigra pars compacta (SN) [1]. Identification of several
genetic risk factors has led to a significant advance in
our understanding of PD pathogenesis. To date, muta-
tions in several genes, such as SNCA (α-synuclein),
Leucine-rich repeat kinase 2 (LRRK2), DJ-1, PARK2
(PARKIN), and PTEN-induced putative kinase 1 (PINK1)
[1], have been shown to cause familial early-onset PD, ac-
counting for 5–10 % of all cases [2].
Mounting evidence suggests mitochondrial dysfunction
as a central mechanism in PD pathogenesis [3]. For in-
stance, mitochondrial toxins, such as MPTP and rotenone,
induce parkinsonism in animal models and human [4].
Moreover, damage to mitochondrial DNA in SN is in-
creased in aging and PD patients [5, 6]. Furthermore, the
activity of complex I is reduced in SN of PD patients [7,
8]. Therefore, a better understanding of how the integrity
and function of mitochondria are maintained following in-
sults may provide novel opportunities for PD treatment.
Mutations in PARKIN and PINK1 are the leading causes
of autosomal recessive PD [9, 10]. Together, they function-
ally mediate the stress-activated, selective clearance of
impaired mitochondria via autophagic degradation (termed
mitophagy) [11], supporting the idea that deficits in
mitochondria quality control may be a core mechanism
underlying PD pathogenesis. PINK1, a mitochondrial
serine/threonine kinase, is maintained at low levels
under normal physiological conditions. Upon mitochon-
drial damage, PINK1 is quickly stabilized on damaged
mitochondria, which leads to translocation of cytosolic
Parkin to damaged mitochondria [11–13]. PINK1 activates
Parkin by phosphorylating it at Ser65. Once activated, Par-
kin, an E3 ubiquitin ligase, selectively tags the damaged
mitochondria for mitophagic clearance by ubiquitinating
multiple mitochondrial proteins [14, 15]. Recently, several
groups discovered that PINK1 also phosphorylates ubi-
quitin at Ser65 (pUbS65) and PINK1-dependent phos-
phorylation of ubiquitin is required for translocation
and activation of Parkin to initiate mitophagy [16–18].
Moreover, pUbS65 has been suggested to accumulate
with mitochondrial stress, age, and disease [19] and to
serve as a specific signal for recognition by autophagy
receptors [20, 21]. Therefore, accumulation of pUbS65
is a hallmark of mitochondrial stress/damage. Beyond
their roles in mitophagy, mounting evidence suggested
that both PINK1 and Parkin have neuroprotective roles
against various insults, such as oxidative stress and PD-
relevant toxins, although the underlying mechanisms
still remain elusive [22, 23].
Given its critical roles in mitochondrial homeostasis
and neuroprotection, the mechanism of how PINK1 ex-
pression is regulated has been under intense investiga-
tions. Although PINK1 regulation at the post-translational
level has been extensively studied [24], little is known
about the regulation mechanism of PINK1 at transcrip-
tional or translational levels. microRNAs (miRNAs) have
been gaining growing attention as key regulators of pro-
tein coding genes [25, 26]. Small non-coding miRNAs,
~22 nucleotides, are generated from primary transcripts
via sequential cleavages by Drosha, ribonuclease type III
(DROSHA) and Dicer 1, ribonuclease type III (DICER1)
complexes [27]. miRNAs regulate expression of their
target genes by binding to cognate messenger RNAs
(mRNAs), leading to translational repression [27].
Thus far, a few miRNAs are identified as regulators of
PD-associated genes, such as SNCA, LRRK2, and DJ-1
[28–31]. However, post-transcriptional regulation of
human PINK1 by miRNAs is poorly defined.
Here, we identified a novel regulatory mechanism of
PINK1 by miR-27a/b via targeting its 3′UTR. We dem-
onstrated that miR-27a and miR-27b inhibit PINK1
stabilization, thereby preventing autophagic degradation
of impaired mitochondria.
Results
PINK1 expression is regulated by miRNAs
PINK1 mRNA (NM_032409) has a long 3′UTR, ~840
nucleotides, raising the possibility that its expression
may be regulated by miRNAs which often target 3′UTR
sequences. The mature miRNAs bind to their target
mRNAs through incorporation into the RNA-induced
silencing complex (RISC) which is composed of Argonaute
(AGO) and several other partners [32]. To determine if
PINK1 expression is regulated by miRNAs, we first assessed
whether human PINK1 mRNA is associated with RISC
complex using AGO-specific RNA immunoprecipitation
method in HeLa cells (Fig. 1a). AGO2-bound miRNA/
mRNA complexes were first pulled down with an AGO-
specific antibody. Non-specific IgG served as negative con-
trol. PINK1 mRNA levels were then analyzed by qRT-PCR.
Pull-down with anti-AGO antibody resulted in dramatic in-
crease of PINK1 mRNA levels compared to the control
IgG, whereas AGO2 knock-down with siRNA markedly de-
creased PINK1 mRNA levels pulled down by anti-AGO
antibody (Fig. 1b, c). We next tested whether inhibition of
miRNA biogenesis via DICER1 knock-down would affect
PINK1 protein levels. As expected, DICER1 knock-down
decreased miRNA levels in HeLa cells (Additional file 1).
Compared to the negative control, DICER1 knock-down
with siRNA significantly increased PINK1 protein levels in
HeLa cells (Fig. 1d, e). Collectively, our data indicate that
human PINK1 expression is regulated by miRNAs.
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miR-27a/b suppress human PINK1 expression by directly
targeting 3′UTR of its mRNA
To identify potential miRNAs that directly regulate
PINK1 expression, we first searched miRNAs that have
putative binding sites in the 3′UTR of human PINK1
mRNA by utilizing several miRNA-target prediction al-
gorithms as described previously [33]. Among several
candidates, we focused on miR-27a and miR-27b (here-
after referred to as miR-27a/b) because 1) miR-27a/b are
commonly predicted by several algorithms to have seed
match sequences in the 3′UTR of human PINK1 mRNA
(Fig. 2a and Additional file 2a), 2) miR-27a/b are expressed
in SN of human midbrain (Additional file 2a) [34–36], 3)
miR-27a/b have multiple putative binding sites in the 3′
UTR of human PINK1 mRNA with low binding free
energies (Additional file 2b) [37]. Of note, both putative
binding sites of miR-27a/b in the 3′UTR of PINK1
mRNA are well conserved in primates, such as human,
chimpanzee, and monkey, but not in rodents, such as
rat and mouse (Additional file 3), raising the possibility
of primate-specific regulation of PINK1 expression by
miR-27a/b.
To determine if miR-27a/b directly suppress PINK1
expression by targeting its 3′UTR, we performed a lucif-
erase assay with the reporter construct containing the
entire 3′UTR of human PINK1 mRNA downstream of
luciferase (Fig. 2b). miR-27a/b significantly suppressed
the expression of luciferase in HeLa cells (Fig. 2c). Muta-
tions in either seed match site1 or site2 significantly in-
creased luciferase activities compared to wild-type (Fig. 2c).
Moreover, a combined mutation in both seed match sites
(Mut 1&2) completely abolished the miR-27a/b-mediated
reduction of luciferase activities, indicating that both seed
match sites are functional (Fig. 2c). There was no difference
in the levels of miR-27a and miR-27b expressed between
the miR transfected groups (Additional file 4). To deter-
mine if miR-27a/b affect PINK1 protein levels, we first
transfected synthetic miR-27a, miR-27b, or negative control
to human HeLa cells (Additional file 5a). Overexpression of
miR-27a/b markedly decreased PINK1 protein levels in
HeLa cells (Fig. 2d, e). A combination of miR-27a and
miR-27b did not further decrease PINK1 levels in
HeLa cells, suggesting that both miR-27a and miR-27b
target the same site in the 3′UTR of PINK1 mRNA
(Additional file 6). To evaluate the effect of miR-27a/b
in another cell type, we tested M17 cells. miR-27a/b also
suppressed PINK1 expression in human dopaminergic-like
M17 cells (Fig. 2f, g).
Next, we examined whether endogenous miR-27a/b
regulate PINK1 expression. To inhibit miR-27a/b func-
tion, we used locked nucleic acid (LNA)-based anti-
miR that is nuclease-resistant single-stranded antisense
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Fig. 1 Regulation of PINK1 by miRNA. a Schematic diagram of AGO-specific RNA immunoprecipitation assay. b, c PINK1 mRNAs are associated
with miRNA/RISC complex. HeLa cells were transfected with 50 nM of AGO2 siRNA or negative control. 48 h post-transfection, AGO2-bound
mRNAs were pulled down from cell lysates with 2A8 anti-AGO2 antibody or non-specific IgG antibody. PINK1 mRNA levels were then measured
by qRT-PCR. siRNA against AGO2 served as a quality control for AGO-specific RNA immunoprecipitation assay. PINK1 mRNA levels were quantified
as a percentage of group 1 (n = 6, two-way ANOVA). d, e Knock-down of DICER1 increased PINK1 protein levels. HeLa cells were transfected with
50 nM DICER1 siRNA (DICER1 KD) or negative control (Ctl). 48 h post-transfection, cells were harvested for Western blot. The arrowhead indicates
a full-length PINK1 band and the asterisk indicates a non-specific band. Each protein level was normalized to corresponding GAPDH level and
quantified as a percentage of control (n = 4, t-test). Values are mean ± SEM (n.s. = non-significant, **p < 0.01, ***p < 0.001)
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oligonucleotides complementary to their target miRNAs
[38]. Due to the high similarity in the mature sequences of
miR-27a and miR-27b, single anti-miR (denoted as anti-
miR-27a/b) inhibited both miR-27a and miR-27b (Fig. 3a
and Additional file 5b). Inhibition of endogenous miR-
27a/b significantly increased luciferase activities from the
reporter construct with WT PINK1 3′UTR, whereas com-
bined mutations of both seed match sites blocked the
anti-miR-27a/b-mediated induction of luciferase activities
in HeLa cells (Fig. 3b). Moreover, Inhibition of endogen-
ous miR-27a/b significantly increased PINK1 protein
levels in HeLa cells as well as M17 cells (Fig. 3c-f ). Col-
lectively, these data indicate that miR-27a/b suppress
human PINK1 expression by directly targeting 3′UTR
of its mRNA.
PINK1 translation is indispensable for the accumulation of
PINK1 upon mitochondrial damage
PINK1 protein is rapidly and constitutively degraded in
healthy mitochondria by mitochondrial proteases, whereas
mitochondrial damage allows PINK1 to accumulate on
the outer membrane of the damaged mitochondria [39].
However, it has not been well determined whether tran-
scription and/or translation step of PINK1 may contribute
to the accumulation of PINK1 protein upon mitochondrial
damage. Given a low basal level of PINK1 protein and a
rapid build-up of PINK1 protein upon mitochondrial
damage, we hypothesized that new synthesis of PINK1
mRNA together with post-translational stabilization
may contribute to the accumulation of PINK1 upon
mitochondrial damage. Thus, we first examined whether
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Fig. 2 miR-27a/b suppress human PINK1 expression. a Schematic diagram of the conserved target sites of miR-27a/b in the 3′UTR of human PINK1
mRNA. Seed sequences were indicated in red. Asterisks (*) indicate the conserved nucleotides. b Schematic diagram of the luciferase reporter
plasmids. The reporter constructs contain the full-length 3′UTR of human PINK1 mRNA with wild-type (WT) or mutated (Mut) seed match sites
downstream of Renilla luciferase gene. c Overexpression of miR-27a/b decreased luciferase activities in HeLa cells. Cells were transfected with
miR-27a/b or negative control (Ctl) along with reporter constructs as indicated. 48 h post-transfection, luciferase activities were measured (n = 4,
one-way ANOVA). Renilla luciferase activity was normalized to the corresponding firefly luciferase activity. d-g Overexpression of miR-27a/b decreased
PINK1 protein levels in HeLa (D-E) and M17 cells (F-G). Cells were transfected with miR-27a/b or negative control (Ctl). 48 h post-transfection, cells were
harvested for Western blot (n = 4, t-test). PINK1 protein level was normalized to corresponding GAPDH level and quantified as a percentage of control.
Data are shown as a percentage of control. Values are mean ± SEM (n.s. = non-significant, **p < 0.01, ***p < 0.001)
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PINK1 mRNA levels are altered by mitochondrial
damage. PINK1 mRNA levels were not affected by mito-
chondrial damages induced by either carbonyl cyanide
m-chlorophenylhydrazone (CCCP, mitochondrial un-
coupler) or combination of oligomycin (inhibitor of ATP
synthase) and antimycin (inhibitor of mitochondrial
respiratory chain complex III) in HeLa cells (Fig. 4a).
Notably, blocking translation with cycloheximide (CHX)
completely abolished the accumulation of PINK1 protein
by CCCP (Fig. 4b, c). Taken together, these data suggest
that PINK1 translation is critical for the accumulation of
PINK1 upon mitochondrial damage.
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Fig. 3 Inhibition of endogenous miR-27a/b function increases human PINK1 expression. a Schematic diagram of sequence alignment of miR-27a/b
and anti-miR-27a/b. Asterisks (*) indicate conserved nucleotides. b Inhibition of endogenous miR-27a/b function increased luciferase activities in HeLa
cells. Cells were transfected with the reporter constructs containing the full-length 3′UTR of human PINK1 mRNA with wild-type (WT) or mutated (Mut)
seed match sites downstream of Renilla luciferase gene. 48 h post-transfection, luciferase activities were measured (n = 4, t-test). c-f Inhibition
of endogenous miR-27a/b increased PINK1 protein levels in HeLa (C-D) and M17 cells (E-F). Cells were transfected with 150 nM of anti-miR-27a/b or
anti-control (anti-Ctl). 48 h post-transfection, cells were harvested for Western blot. PINK1 protein level was normalized to corresponding GAPDH level
and quantified as a percentage of control (n = 4, t-test). Data are shown as a percentage of control. Values are mean ± SEM (n.s. = non-significant,
**p < 0.01, ***p < 0.00)
a b
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Fig. 4 PINK1 translation is critical for the accumulation of PINK1 upon mitochondrial damage. a PINK1 mRNA levels were not altered by mitochondrial
damage. HeLa cells were incubated with 10 μM CCCP or combination of 10 μM oligomycin and 4 μM antimycin for 2 h and then, PINK1 mRNA levels
were measured by qRT-PCR. PINK1 mRNA level was normalized to the corresponding GAPDH levels and quantified as a percentage of control (n= 8,
t-test). b, c Translation is involved in PINK1 accumulation upon CCCP treatment. HeLa cells were first pre-incubated with 100 μM cycloheximide (CHX)
for 2 h and then washed. Cells were further incubated with 10 μM CCCP with or without CHX for 2 h (n = 4, two-way ANOVA). Values are mean ± SEM
(n.s. = non-significant, ***p < 0.001)
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miR-27a/b inhibit PINK1 accumulation upon
mitochondrial damage
Because miR-27a/b suppress PINK1 expression at the
translational level, we next examined whether miR-27a/b
influence PINK1 accumulation upon mitochondrial dam-
age. miR-27a/b-mediated suppression of PINK1 dra-
matically reduced the PINK1 accumulation upon CCCP
treatment compared to the negative control (Fig. 5a, b),
whereas inhibition of miR-27a/b further increased PINK1
accumulation compared to the negative control
(Fig. 5c, d). Furthermore, miR-27a/b showed similar
effects on PINK1 accumulation upon combined treat-
ment of oligomycin and antimycin (Fig. 5a-d). Taken
together, our data suggest that the accumulation of
PINK1 upon mitochondrial damage is strongly regu-
lated by expression levels of miR-27a and miR-27b.
miR-27a/b prevent the accumulation of phospho-ubiquitin
upon mitochondrial damage
Recent studies demonstrated that PINK1 phosphorylates
ubiquitin at Ser65 (pUbS65) upon mitochondrial damage
[16–18]. Ubiquitin phosphorylation by PINK1 plays a
critical role in the activation and mitochondrial trans-
location of Parkin [16–18]. We also observed that
pUbS65 levels were markedly increased by CCCP and
overexpression of PINK1 further increased the pUbS65
accumulation by CCCP in HeLa cells (Fig. 6a). However,
overexpression of PINK1 did not affect pUbS65 levels
under the basal condition without CCCP treatment
(Fig. 6a), suggesting that ubiquitin kinase activity of
PINK1 is activated specifically upon mitochondrial damage.
In line with these data, overexpression of miR-27a/b
inhibited the accumulation of pUbS65 upon CCCP treat-
ment compared to the negative control (Fig. 6c, d), whereas
inhibition of miR-27a/b further increased pUbS65 levels in
the presence of CCCP compared to the negative control
(Fig. 6e, f). In contrast, pUbS65 levels were not affected by
either overexpression or inhibition of miR-27a/b under the
basal condition without CCCP treatment (Fig. 6c-f). Taken
together, our data demonstrate that miR-27a/b prevent
the accumulation of pUbS65 upon mitochondrial damage
by suppressing PINK1 expression.
miR-27a/b prevent Parkin translocation to mitochondria
upon mitochondrial damage
PINK1-dependent translocation of cytosolic Parkin to
damaged mitochondria is a prerequisite for mitophagy
[11]. To determine if miR-27a/b prevent Parkin trans-
location upon mitochondrial damage, we transfected
miR-27a/b or negative control to HeLa cells stably
a
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Ctl miR-27a miR-27b
50 kDa
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Fig. 5 miR-27a/b inhibit PINK1 accumulation upon mitochondrial damage. a, b Overexpression of miR-27a/b inhibited PINK1 accumulation upon
mitochondrial damage. 48 h post-transfection, HeLa cells were treated with 10 μM CCCP or combination of 10 μM oligomycin and 4 μM antimycin as
indicated for 2 h (n = 4, two-way ANOVA). c, d Inhibition of endogenous miR-27a/b increased PINK1 accumulation upon CCCP treatment. (n = 4,
two-way ANOVA). PINK1 levels were normalized to corresponding GAPDH level and quantified as a percentage of control. Values are mean ± SEM
(n.s. = non-significant, *p < 0.05, **p < 0.01, ***p < 0.001)
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expressing Parkin. After inducing mitochondrial dam-
age by CCCP for 2 h, mitochondrial fractions were
separated from total cell lysates and then analyzed by
Western blot (Fig. 7a). Compared to the negative con-
trol, miR-27a/b strongly inhibited Parkin translocation
to mitochondria as well as accumulation of active form
of LC3 (LC3-II), an autophagic marker, upon CCCP treat-
ment (Fig. 7a, b).
To confirm our biochemical analysis of miR-27a/b ef-
fect on Parkin translocation, we also quantified Parkin
translocation by High Content Imaging. After trans-
fected with a negative control or miR-27a/b, HeLa cells
expressing GFP-Parkin were treated with CCCP for 2 h,
stained with a nuclear dye, and imaged. Parkin trans-
location was measured by assessing the ratio of cyto-
plasmic and nuclear GFP signal as described previously
[40]. miR-27a/b overexpression markedly decreased the
levels of Parkin colocalized with mitochondria marker
TOM20, compared to the negative control (Fig. 7c, d).
Taken together, our data demonstrate that miR-27a/b
prevent the induction of mitophagy by suppressing
PINK1 expression.
miR-27a/b inhibit the lysosomal degradation of damaged
mitochondria
Damaged mitochondria are selectively tagged by a combin-
ation of PINK1 and Parkin and then, delivered to lysosome
for hydrolytic degradation [11]. Therefore, we next exam-
ined whether miR-27a/b inhibit the delivery of damaged
mitochondria to lysosome by using mitochondria-targeting
Keima (mtKeima) [41]. Keima is a fluorescent protein de-
rived from coral which is resistant to lysosomal proteases
and changes its color upon pH change. mtKeima is engi-
neered to localize in mitochondria and changes its color
upon a fusion of neutral autophagosome with acidic lyso-
some [41]. After transfected with a negative control, PINK1
siRNA, or miRNAs as indicated, HeLa cells expressing
mtKeima were treated with CCCP for 12 h and imaged.
Lysosomal delivery of damaged mitochondria was mea-
sured by assessing the ratio of acidic and neural Keima
f
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Fig. 6 miR-27a/b prevent pUbS65 accumulation upon mitochondrial damage. a, b Overexpression of PINK1 increased pUbS65 accumulation in
HeLa cells only when incubated with CCCP. 48 h post-transfection, cells were incubated with 10 μM CCCP for 2 h and pUbS65 levels were
determined by Western blot (n = 3, two-way ANOVA). c, d Overexpression of miR-27a/b inhibited pUbS65 accumulation by CCCP in HeLa cells
(n = 4, two-way ANOVA). e, f Inhibition of endogenous miR-27a/b increased pUbS65 accumulation by CCCP in HeLa cells (n = 4, two-way ANOVA).
PINK1 levels were normalized to corresponding GAPDH level and quantified as a percentage of control. Values are mean ± SEM (n.s. = non-significant,
**p < 0.01, ***p < 0.001)
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signal as described previously [41]. As a positive control for
the assay, we first tested the effect of PINK1 knockdown.
PINK1 knockdown dramatically decreased the lysosomal
delivery of damaged mitochondria, validating our assay per-
formance (Additional file 7a, b). miR-27a/b overexpression
significantly decreased the lysosomal delivery of damaged
mitochondria (Fig. 8a, b). Autophagic clearance of damaged
mitochondria was further assessed by monitoring the deg-
radation of COX2, a mitochondrial inner membrane pro-
tein. miR-27a/b inhibited the degradation of COX2 upon
mitochondrial damage, compared to a negative control miR
(Fig. 8c, d). These two independent assays indicate that
miR-27a/b inhibit autophagic degradation of damaged
mitochondria by lysosome.
Induction of miR-27a/b under the chronic mitophagic flux
condition
To determine if there is a regulatory interaction between
miR-27a/b and mitophagy, we next examined the change
in miR-27a/b levels upon mitochondrial damage at dif-
ferent time points. Interestingly, the levels of miR-27a/b
were dramatically increased under the chronic mitophagic
flux condition in HeLa cells (Fig. 9a, b). miR-27a and miR-
27b are produced from miR-23a ~ 27a ~ 24–2 cluster at
chromosome 19p13 and miR-23b ~ 27b ~ 24–1 cluster at
chromosome 9q22, respectively (Additional file 8a).
The mature miRNAs of miR-23a ~ 27a ~ 24–2 cluster
are known to be derived from a single primary transcript
[42]. The miRNAs of miR-23b ~ 27b ~ 24–1 cluster are
a b
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Fig. 7 miR-27a/b prevent Parkin translocation to mitochondria upon mitochondrial damage. a, b 48 h post-transfection, HeLa cells were incubated
with 10 μM CCCP for 2 h. After isolating the mitochondria-enriched fractions, Parkin translocation and LC3-II were assessed by Western blot. Each
protein level was normalized to corresponding mitochondrial loading control (SOD2) level and quantified as a percentage of control (n = 3, two-way
ANOVA). Purity of mitochondrial fraction was assessed by monitoring p38 cytosolic and VDAC1 mitochondrial markers. PN; post-nuclear, C; cytoplasm,
M; mitochondrial (A). c, d 48 h post-transfection, HeLa cells stably expressing GFP-Parkin were visualized by GFP, a mitochondrial marker (TOM20)
antibody, and a nuclear dye (Hoechst) as indicated. Scale bars correspond to 10 μm. Parkin translocation was quantified as the ratio of cytoplasmic to
nuclear GFP signal and the resulting ratios were normalized to control. Data were collected from 4 independent replicates (n > 1000 cells) and are
shown as a percentage of control. Values are mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)
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transcribed independently but regulated by the same pro-
moter [43]. Therefore, the expression of miRNAs in these
clusters is expected to be regulated together. In the same
manner with miR-27a/b, the levels of miR-23a/b were also
increased under the chronic mitophagic flux condition
(Additional file 8b, c). However, there was no change in
the levels of several other miRNAs which are not included
in these clusters (Additional file 8d). These data suggest
that the change of miRNA expression under the
chronic mitophagic flux is not a general nonspecific
phenomenon affecting all miRNAs. Taken together,
miR-27a/b are endogenous inhibitors of mitophagy and
may function as a negative feedback loop under chronic
mitophagic flux (Fig. 9c).
Discussion
Mitochondria play critical roles in a variety of cellular
functions, such as energy production, calcium homeostasis,
and apoptosis [44]. Mitochondrial dysfunction has been
suggested as a key factor in several diseases, including
metabolic diseases and neurodegenerative diseases [44, 45].
Therefore, maintaining mitochondrial homeostasis is crit-
ical for cellular functions and health. In eukaryotic cells,
mitochondrial homeostasis is maintained by mitochondrial
quality control system which is a dynamic process co-
ordinated by fission and fusion, mitophagy, transport,
and biogenesis [46].
PINK1 plays critical roles in mitochondrial quality
control, particularly in induction of mitophagy [39]. Al-
though post-translational stabilization of PINK1 upon
mitochondrial damage has been extensively studied, our
understanding of PINK1 expression regulation at the
transcriptional or translational levels, in particular, by
miRNAs is still very limited. Here, we demonstrated that
miR-27a/b negatively regulate human PINK1 through
translational inhibition by directly targeting 3′UTR of its
mRNA. Of note, our data suggest that PINK1 translation
is critical for the accumulation of PINK1 protein upon
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Fig. 8 miR-27a/b inhibit the degradation of mitochondria via lysosome upon mitochondrial damage. a, b miR-27a/b inhibit the delivery of
damaged mitochondria to lysosome. 48 h post-transfection, HeLa cells stably expressing mtKeima were treated with CCCP or DMSO for 12 h.
Cells were sequentially scanned using 440/10 nm (neutral) and 548/20 nm (acidic) excitation filters. Scale bars correspond to 100 μm. The
signal intensity of the acidic Keima was divided by the intensity of the neutral mtKeima. Data were collected from 12 independent replicates
and are shown as a percentage of control (n > 300 cells, two-way ANOVA). c, d miR-27a/b inhibit the degradation of COX2 upon mitochondrial
damage. 48 h post-transfection, HeLa cells were treated with 10 μM CCCP or DMSO for 16 h. The degradation of damaged mitochondria was assessed
by monitoring the levels of COX2, a mitochondrial inner membrane protein, by Western blot (n = 4, two-way ANOVA). Values are mean ± SEM
(n.s. = non-significant, *p < 0.05, ***p < 0.001)
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mitochondrial damage. We further demonstrated that
translational inhibition of PINK1 by miR-27a/b suppresses
the autophagic clearance of damaged mitochondria by
lysosome.
Our results demonstrated that endogenous PINK1
levels are actively regulated by the expression levels of
miR-27a/b under the basal condition. Inhibition of en-
dogenous miR-27a/b significantly increased the PINK1
protein levels under the basal condition. These data sug-
gest that endogenous miR-27a/b critically contribute to
maintaining the level of PINK1 protein lower than the
threshold required for mitophagic induction and thereby,
may protect cells from the untoward loss of mitochondria
under the basal condition. Upon mitochondrial damage,
mitophagic influx is regulated by miR-27a/b through their
direct regulation of PINK1 expression, suggesting the roles
of miR-27a/b as gate-keepers of mitophagic pathway.
Interestingly, the expression of miR-27a/b is dramatically
increased under the chronic mitophagic flux condition.
Given the critical roles of mitochondria in cellular homeo-
stasis and energy metabolism, the continuous loss of mito-
chondria will be toxic to the cells. Our data suggest that
miR-27a/b may function as a negative feedback loop under
the chronic mitophagic flux condition in order to protect
cells from the depletion of mitochondria. Determining
how the expression of miR-27a/b is regulated under the
basal condition and mitochondrial stress condition will
provide further insights into the regulatory mechanism of
PINK1 and mitophagy.
miRNAs are getting more attention as critical regulators
for many cellular processes. So far, only few miRNAs have
been shown to regulate mitophagy. For example, miR-137
inhibits mitophagy by targeting FUNC1 and NIX [47].
miR-320a promotes mitophagy by targeting VDAC1 [48].
c
a b
Lysosome
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miR-27a/b
AAAAA
Lysosome
PINK1 mRNA
AAAAA
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RISC
miR-27a/b
AAAAA
AAAAA
Chronic 
mitophagic flux
DNA
Fig. 9 The levels of miR-27a/b are increased under chronic mitophagic flux condition. a, b HeLa cells were incubated with DMSO, 10 μM CCCP,
or combination of 10 μM oligomycin and 4 μM antimycin as indicated. miR-27a/b levels were measured by qRT-PCR and normalized to corresponding
U6 levels. Data are shown as fold changes relative to the DMSO controls. Values are mean ± SEM (t-test, **p < 0.01, ***p < 0.001). c A proposed role of
miR-27a/b in mitophagy. Upon chronic mitophagic flux, the levels of miR-27a/b are increased and miR-27a/b function as a negative feedback
loop to turn off excessive mitophagic flux. Upon the induction of miR-27a/b expression, the translation of PINK1 mRNA is inhibited by miR-27a/b.
Consequently, the level of PINK1 protein in mitochondria decreases and thereby, autophagic degradation of the damaged mitochondria by lysosome
is inhibited (Left panel). In contrast, PINK1 translation and lysosomal clearance of damaged mitochondria are increased when PINK1 inhibition
mediated by miR-27a/b was disinhibited by the low levels of miR-27a/b (Right panel)
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miR-351 and miR-125a are also known to regulate
mitophagy [49]. These studies suggest that mitophagy
is actively regulated by diverse miRNAs at multiple
levels. In this study, we report that endogenous miR-27a/b
play a critical role in PINK1 expression, thereby in mito-
phagy. Therefore, our study significantly contributes to
understanding of the regulation mechanism of mitophagy,
in particular, by miRNAs. Loss of PINK1 has been asso-
ciated with mitochondrial dysfunction in Drosophila,
mouse, and human, suggesting that the roles of PINK1
in mitochondrial quality control may be evolutionally
conserved [50, 51]. Although the function of PINK1
may be conserved across evolution, our study suggests
that miR-27a/b may exert a primate-specific regulation
of PINK1 and mitophagy. miR-27a and miR-27b are
produced from miR-23a ~ 27a ~ 24–2 and miR-23b ~
27b ~ 24–2 cluster, respectively. These paralogous clusters
also produce miR-23a, miR-23b, and miR-24. Interestingly,
all of them are known to regulate autophagy-associated
genes. For example, miR-23a, miR-23b, and miR-24 sup-
press AMBRA1 [52], ATG12 [53, 54], and ATG4A [55],
respectively. Although the role of ATG4A in mitophagy is
unclear, AMBRA1 and ATG12 positively regulate mito-
phagy [56–58]. Therefore, it is tempting to speculate that
miRNAs in those clusters may coordinate their function
to effectively regulate mitophagy.
PINK1 is expressed ubiquitously in neurons through-
out the human brain [59, 60]. Several previous studies
showed that miR-27a/b are expressed in human mid-
brain [34–36]. Because we demonstrated that endogen-
ous miR-27a/b regulate PINK1 expression in human
dopaminergic-like M17 cells, our study raises the possi-
bility that miR-27a/b may regulate PINK1 expression in
dopaminergic neurons of the human midbrain. Although
the role of PINK1 in mitophagy in neurons is controver-
sial [61], PINK1 also plays crucial roles in mitochondria
trafficking, spine morphogenesis, and vulnerability to
excitotoxicity in neurons [23]. Therefore, further studies
are warranted to determine the roles of miR-27a/b in
dopaminergic neurons of the human brain.
Recent miRNA profiling studies identified several miR-
NAs that are dysregulated in the affected regions of PD
brains [35, 36, 62]. However, there are significant discrep-
ancies between these studies, likely due to methodological
differences as well as the heterogeneity of sample popula-
tion, disease stages, and brain subregions examined. More-
over, relatively small sample sizes in those studies make it
difficult to draw a firm conclusion whether expression of
miR-27a/b and other miRNAs in miR-23a ~ 27a ~ 24–2
and miR-23b ~ 27b ~ 24–2 cluster are dysregulated in the
brains of PD patients. Closer examination of miR-27a/b
expression in different brain cell types at different stages
of PD is needed to gain further insight into the putative
roles of miR-27a/b in PD pathogenesis.
Conclusions
PINK1 is genetically associated with Parkinson’s disease
(PD) and plays critical roles in maintaining mitochondrial
homeostasis. In this study, we identified a novel regulatory
mechanism of PINK1 by miR-27a and miR-27b at the
translational level. Our research highlights that protein
translation step of PINK1 is critical for PINK1 accumu-
lation upon mitochondrial damage. Consequently, the
accumulation of PINK1 and mitophagic flux upon
mitochondrial damage is strongly regulated by expression
levels of miR-27a and miR-27b. Our results represent a
significant advance in our understanding of translational
control of PINK1 expression and mitophagy by miRNAs.
Methods
Cell culture
Human cervical HeLa and dopaminergic-like M17 cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, 11965084) or Opti-MEM I (Invi-
trogen, 31985070) with 10 % fetal bovine serum (FBS,
Invitrogen, 16000044) and 1 % penicillin/streptomycin
at 37 °C in a humidified 5 % CO2 incubator, respectively.
Synthetic miR-27a/b and a negative control miR (Catalog #
M-03-D) were from Insight Genomics. Anti-miR-27a/b
(4101393–001) and anti-negative control (199006–001)
were from Exiqon. AGO2 (E-004639-00-0005), DICER1
siRNA (M-003483-00-0005), and negative siRNA con-
trol (D-001206-14-05) were from Dharmacon. PINK1
siRNA (5′-GACGCTGTTCCTCGTTATGAA-3′) was from
Qiagen.
Quantitative Real Time Polymerase Chain Reaction
(qRT-PCR)
Total RNAs were extracted using TRIzol® Reagent (Invi-
trogen) and reverse transcribed with High Capacity
cDNA Reverse Transcription kit (Applied Biosystems)
for mRNAs or with Mir-X™ miRNA First-Strand Synthe-
sis Kit (Clontech) for miRNAs except miR-27a/b accord-
ing to the manufacturer’s guides. Quantitative PCR was
performed with Power SYBR Green PCR Master Mix,
ABI 7500, and ABI 7900 (Applied Biosystems) using de-
fault thermal cycling program. PINK1 mRNA levels were
measured with PINK1 forward primer: GGAGGAGTAT
CTGATAGGGCAG and reverse primer: AACCCGGTGC
TCTTTGTCAC. miR-27a/b levels were measured as pre-
viously described [63]. Mature sequences and universal re-
verse primer were used for all other miRNAs. GAPDH
and U6 were used as normalization controls for mRNA
and miRNA, respectively.
AGO-specific RNA immunoprecipitation assay
RNA immunoprecipitation assay was carried out as pre-
viously described [64]. Briefly, HeLa cells were trans-
fected with 50 nM of AGO2 siRNA or negative control.
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48 h after transfection, AGO2-bound mRNAs were
pulled down from cell lysates with 2A8 anti-AGO2 anti-
body. Then, RNAs were extracted using TRIzol® Reagent
and PINK1 mRNA levels were measured by qRT-PCR.
Luciferase assay
The entire 3′UTR of human PINK1 mRNA (NM_032409,
1841–2660) was cloned into psiCHECKTM-2 vector at
XhoI/NotI site downstream of Renilla luciferase. psi-
CHECKTM-2 vector also contains a constitutively
expressed firefly luciferase gene that was used to
normalize Renilla luciferase activity. Mutations in seed
match sites were introduced using KOD-Plus-Mutagenesis
Kit (TOYOBO). HeLa cells were plated at a density of
2.4 × 104 cells per well in a 96-well plate a day before trans-
fection. Cells were transfected with 40 nM of miR-27a/b or
negative control or with 150 nM of anti-miR-27a/b or
anti-control along with 40 ng of luciferase reporter vec-
tor as indicated. 48 h post-transfection, luciferase activ-
ity was measured using the Dual-Glo Luciferase Assay
System (Promega).
Mitochondrial fractionation
48 h post-transfection as indicated, cell were treated with
10 μM CCCP for 2 h and then, mitochondrial fraction was
prepared as previously described [65].
High Content Imaging and immunofluorescence staining
For quantification of Parkin translocation, 40 nM miRNA
was transfected to HeLa cells stably expressing GFP-
Parkin in 384-well imaging plates. 48 h post-transfection,
cells were treated with 10 μM CCCP for 2 h. Cells were
then fixed in 4 % paraformaldehyde, stained with Hoechst
33342 (Invitrogen), and imaged on a BD Pathway 855 sys-
tem (Becton Dickinson Biosciences). Parkin translocation
was analyzed as previously described [40]. Analyzed were
4 independently transfected wells each with a total num-
ber of > 1000 cells per condition. After imaging on the BD
pathway, plates were stained with mitochondrial marker,
translocase of outer mitochondrial membrane 20 homolog
(yeast) (Tom20), using anti-TOM20 antibody (Proteintech,
11802-1-AP). Confocal fluorescent images were taken with
a 40 x Plan-Apochromat objective using a Zeiss AxioObser-
ver equipped with an ApoTome Imaging System (Zeiss).
For the analysis of mitochondrial degradation, delivery
of the damaged mitochondria to lysosome was visualized
and quantified as previously described [41] with some
modifications. Briefly, 40nM miRNA was transfected in
HeLa cells stably expressing mitochondria-targeting Keima
(mtKeima) in 384-well imaging plates. 48 h post-
transfection, cells were treated with 4 μM CCCP for 12 h.
Cells were imaged live after addition of Hoechst 33342 on
the BD Pathway system. Acquisition was performed with a
2x2 montage (no gaps) after laser autofocus. 440/10 nm
and 548/20 nm excitation filter were used for neutral and
acidic Keima, respectively. Emission was filtered through a
595 nm longpass dichroic filter. 570 nm and 645/75 nm
emission filters were used for neutral and acidic Keima, re-
spectively. Raw images were processed using the build-in
AttoVision V1.6 software. Regions of interest (ROIs) were
defined as nucleus and cytoplasm using the build-in
‘RING - 2 outputs’ segmentation for the Hoechst channel
after applying a shading algorithm. The signal intensity of
the acidic Keima in the cytoplasm was divided by the inten-
sity of the neutral mtKeima. Analyzed were 12 wells per
condition with a minimum of 300 cells per well. PINK1
siRNA was used as a positive control for both assays.
Western blot analysis
Western blots were performed as previously described
[66]. All membranes were blocked with 4 % non-fat
dry milk in TBS/T (Tris buffered saline with 0.125 %
Tween-20) except for pUbS65 which was blocked with
4 % bovine serum albumin (Jackson ImmunoResearch,
001-000-173) in TBS/T. Blots were probed in blocking
buffer with anti-Dicer (Cell Signaling Technology, 5362),
anti-PINK1 (Novus Biologicals, BC100-494), anti-SOD2
(Abcam, ab13533), anti-VDAC1 (Abcam, ab14734), anti-
p38 (Cell Signaling Technology, 9212), anti-COX2 (Abcam,
ab110258), or anti-GAPDH antibody (Santa Cruz, sc-
25778). pUbS65-specific antibody were produced and
characterized as previously described [19].
Statistical analysis
Statistical analyses were performed using two-tailed Stu-
dent’s t-test for the comparison of two groups. The com-
parison of multiple groups more than two were analyzed
using one-way ANOVA or two-way ANOVA test depend-
ing on comparison variables with Tukey’s pot-hoc analysis
as indicated (GraphPad Prism 5).
Additional files
Additional file 1: Knock-down of DICER1 decreased miRNA levels. HeLa
cells were transfected with 50 nM of DICER1 siRNA (DICER1 KD) or
negative control (Ctl). 48 h post-transfection, representative miRNA levels
were analyzed by qRT-PCR and were quantified as a percentage of
control (n = 2). Values are mean ± SEM. (PDF 18 kb)
Additional file 2: Computational prediction of miRNA candidates for
human PINK1. a Computation prediction of miRNAs expressed in human
midbrain with putative binding sites in the 3′UTR of human PINK1 mRNA.
We first searched miRNAs that have putative binding sites in the 3′UTR of
human PINK1 mRNA by utilizing several miRNA-target prediction algorithms,
such as miRanda [67], miRWalk [68], RNAhybrid [37], and Targetscan [69].
Among 49 miRNAs commonly predicted by different algorithms, 7 miRNAs
were known to be expressed in human midbrain [34]. miR-27a/b are pre-
dicted to have 2 putative binding sites in the 3′UTR of human PINK1 mRNA,
while all other miRNAs are predicted to have 1 putative binding site. b
Computational binding prediction of miR-27a/b and their binding sites in
the 3′UTR of human PINK1 mRNA. The binding free energies were
determined by the RNAhybrid algorithm. (PDF 68 kb)
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Additional file 3: a Comparison of 3′UTR sequences of PINK1 mRNAs
from different species. Multiple alignment was performed using ClustalW
program with 3′UTR sequences of PINK1 mRNAs from human (NM_032409),
chimpanzee (XM_001164912), monkey (XM_001096957), rat (NM_001106694),
and Mouse (NM_026880). Seed match sites for miR-27a/b are highlighted in
red. b A phylogenetic tree of 3′UTR sequences of PINK1 mRNA from different
species. The neighbor-jointing tree for the full-length 3′UTR sequences of
PINK1 mRNAs was generated with ClustalW program. (PDF 27 kb)
Additional file 4: The levels of miR-27a (a) and miR-27b (b) in the luciferase
assay. HeLa cells were transfected with miR-27a/b or negative control
(Ctl) along with the reporter constructs as indicated in the X axis. 48 h
post-transfection, miR-27a/b levels were measured by qRT-PCR. Each
level was normalized to the corresponding U6 level. Data are shown as
a fold change relative to the control miR (n = 5, one-way ANOVA).
Values are mean ± SEM (n.s. = non-significant). (PDF 29 kb)
Additional file 5: The levels of miR-27a/b after overexpression (a) and
inhibition (b) of miR-27a/b. HeLa cells were transfected with 40 nM of
negative control (Ctl) or miR-27a/b (A) or with 150 nM of anti-control
(anti-Ctl) or anti-miR-27a/b (B). 48 h post-transfection, miR-27a/b levels were
determined by qRT-PCR. Each level was normalized to the corresponding U6
level. Data are shown as a fold change relative to control (n= 4). Values are
mean ± SEM (n.s. = non-significant, ***p< 0.001, one-way ANOVA (A) or t-test
(B)). (PDF 28 kb)
Additional file 6: A combination of miR-27a and miR-27b does not further
inhibit PINK1 expression compared to each miRNA alone. HeLa cells were
transfected with 80 nM negative control (Ctl), 40 nM Ctl with 40 nM miR-
27a (miR-27a), 40 nM Ctl with 40 nM miR-27b (miR-27b), or 40 nM miR-27a
with 40 nM miR-27b (miR-27a/b). 48 h post-transfection, PINK1 levels were
measured by Western blot and normalized to corresponding GAPDH levels.
Data are shown as a percentage of control (n = 4, one-way ANOVA). Values
are mean ± SEM (***p < 0.001). (PDF 42 kb)
Additional file 7: Knock-down of PINK1 prevents the delivery of
damaged mitochondria to lysosome. 48 h post-transfection with negative
control (si-Ctl) or PINK1 siRNA, HeLa cells stably expressing mtKeima were
treated with 4 μM CCCP or DMSO for 12 h. Cells were sequentially
scanned using 440/10 nm (neutral) and 548/20 nm (acidic) excitation
filters. Scale bars correspond to 100 μm. The signal intensity of the acidic
Keima was divided by the intensity of the neutral mtKeima (a). Data were
collected from 12 independent replicates and are shown as a percentage
of control (n > 300 cells, two-way ANOVA) (b). Values are mean ± SEM
(n.s. = non-significant, ***p < 0.001). (PDF 291 kb)
Additional file 8: a Schematic diagram of miR-23a ~ 27a ~ 24–2 and
miR-23b ~ 27b ~ 24–1 clusters. b, c The levels of miR-23a/b upon
mitochondrial damages. HeLa cells were incubated with DMSO, 10 μM
CCCP, or combination of 10 μM oligomycin and 4 μM antimycin as indicated.
miR-23a/b levels were measured by qRT-PCR and normalized to
corresponding U6 levels. Data are shown as a fold change relative to
DMSO control. d The levels of miR-103, miR-221, and miR-7a upon
mitochondrial damages were measured by qRT-PCR and normalized to
corresponding U6 levels. Values are mean ± SEM (t-test, ***p < 0.001).
(PDF 41 kb)
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